Research programme: cyclin-dependent kinase inhibitors - Johnson & Johnson

Drug Profile

Research programme: cyclin-dependent kinase inhibitors - Johnson & Johnson

Alternative Names: JNJ 7706621; triazine-pyridine biheteroaryl series - Johnson & Johnson

Latest Information Update: 04 Sep 2007

Price : $50

At a glance

  • Originator Johnson & Johnson
  • Class Antineoplastics
  • Mechanism of Action CDC2 protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 04 Sep 2007 Information from the 234th American Chemical Society National Meeting (234th-ACS-2007) added to the introduction
  • 19 Sep 2005 Data presented at the 230th American Chemical Society National Meeting - (230th-ACS-2005) have been added to the Cancer pharmacodynamics section
  • 20 Apr 2004 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top